PSA Total Blood Test: Normal Ranges, Causes & What Your Results Mean

What Is Total PSA?

Prostate-specific antigen (PSA) is a protein enzyme produced almost exclusively by the epithelial cells of the prostate gland, a small walnut-sized organ that sits below the bladder in men. PSA's biological function is to liquefy semen, facilitating sperm motility after ejaculation. Under normal circumstances, only tiny amounts of PSA leak from the prostate into the bloodstream.

The total PSA blood test measures the combined concentration of all forms of PSA circulating in the blood - both the free (unbound) fraction and the complexed (protein-bound) fraction. It is the most widely used biomarker in prostate health assessment and the primary screening test for prostate cancer, though it is important to understand that PSA is organ-specific, not cancer-specific. This means that any condition affecting the prostate, whether benign, inflammatory, or malignant, can raise PSA levels.

Prostate cancer is the most common cancer in men in the UK, with approximately 52,000 new cases diagnosed each year. PSA testing plays a central but complex role in its detection. While PSA screening can identify cancers at an earlier, more treatable stage, it also carries the risk of overdiagnosis - detecting slow-growing cancers that would never have caused symptoms or harm during a man's lifetime. This trade-off underlies much of the debate around population-level PSA screening.

Why Is Total PSA Tested?

Total PSA is measured in a variety of clinical contexts:

• Prostate cancer screening: Men can request a PSA test through their GP as part of the NHS Prostate Cancer Risk Management Programme. While the UK does not have a formal screening programme (unlike breast or bowel cancer), men over 50 can access informed PSA testing after counselling about its benefits and limitations.
• Investigation of urinary symptoms: Lower urinary tract symptoms (LUTS), including frequency, urgency, poor stream, nocturia, and incomplete emptying, may prompt PSA testing alongside other investigations.
• Abnormal digital rectal examination (DRE): A hard, irregular, or nodular prostate on examination warrants PSA testing even if the man is asymptomatic.
• Family history of prostate cancer: Men with a first-degree relative diagnosed with prostate cancer, particularly before age 65, have approximately double the population risk. Earlier and more regular PSA testing may be offered.
• Monitoring after prostate cancer treatment: PSA is the primary surveillance marker following surgery (radical prostatectomy), radiotherapy, or hormone therapy. A rising PSA after treatment may indicate cancer recurrence.
• Active surveillance: Men diagnosed with low-risk prostate cancer who opt for active surveillance rather than immediate treatment have regular PSA monitoring (typically every 3–6 months) to detect disease progression.
• General men's health screening: Many men choose to include PSA in routine health assessments, particularly from their 40s onwards.

Normal Ranges

Total PSA is measured in micrograms per litre (µg/L), which is equivalent to nanograms per millilitre (ng/mL). PSA levels naturally increase with age as the prostate enlarges. The following age-specific reference ranges are widely used in UK clinical practice:

Age Group	Normal PSA Range (µg/L)	Notes
40–49 years	0–2.5 µg/L	Low levels expected in younger men
50–59 years	0–3.5 µg/L	Gradual increase with prostate growth
60–69 years	0–4.5 µg/L	Higher baseline accepted with age
70–79 years	0–6.5 µg/L	Natural age-related elevation
Traditional threshold	4.0 µg/L	Historically used as a referral trigger
Post-radical prostatectomy	< 0.1 µg/L	Should be undetectable; rising levels suggest recurrence

The traditional cut-off of 4.0 µg/L was historically used as the threshold above which further investigation was recommended. However, it is now recognised that there is no single PSA level that definitively separates cancer from no cancer. Approximately 15% of men with a PSA below 4.0 µg/L have prostate cancer on biopsy, and many men with PSA above 4.0 µg/L do not have cancer. Age-specific thresholds and the use of additional parameters (PSA velocity, PSA density, free-to-total PSA ratio, and mpMRI) help improve diagnostic accuracy.

What Do High Total PSA Levels Mean?

An elevated total PSA can result from numerous prostate conditions - both benign and malignant:

• Benign prostatic hyperplasia (BPH): The most common cause of elevated PSA. BPH affects the majority of men over 50 and can raise PSA to 4–10 µg/L or higher without cancer being present. Larger prostates produce proportionally more PSA.
• Prostate cancer: Malignant prostate tissue typically produces more PSA per unit volume than normal tissue. Significantly elevated PSA (above 10 µg/L) carries a higher probability of cancer, though even moderately elevated levels warrant investigation.
• Prostatitis: Bacterial and non-bacterial prostatitis can cause dramatic PSA elevations, sometimes exceeding 20 µg/L, that resolve with treatment. Repeating PSA 6–8 weeks after antibiotic therapy is standard practice.
• Urinary tract infection: UTIs can inflame surrounding prostatic tissue and elevate PSA.
• Recent ejaculation: Ejaculation can raise PSA for 24–48 hours. Abstinence before testing is often recommended.
• Vigorous exercise: Cycling and other activities that place pressure on the perineum can transiently elevate PSA.
• Urological procedures: Catheterisation, cystoscopy, prostate biopsy, and transurethral resection of the prostate (TURP) can significantly raise PSA for weeks.
• Urinary retention: Acute urinary retention causes prostatic distension and PSA elevation.

What Do Low Total PSA Levels Mean?

Low PSA levels are generally reassuring but do not completely exclude prostate cancer:

• Normal prostate health: PSA below 1.0 µg/L in men under 60 is associated with a very low risk of clinically significant prostate cancer over the following decades.
• 5-alpha reductase inhibitor use: Finasteride and dutasteride, prescribed for BPH and male pattern hair loss, reduce PSA by approximately 50% within 6 months. Clinicians must double the measured PSA to interpret results accurately in men taking these medications.
• Obesity: Overweight and obese men tend to have lower PSA due to haemodilution (larger blood volume diluting PSA concentration). Paradoxically, this can mask elevated PSA and delay cancer diagnosis.
• Post-prostatectomy: After radical removal of the prostate, PSA should be undetectable (< 0.1 µg/L). Any measurable PSA after prostatectomy suggests residual or recurrent cancer.
• Effective cancer treatment: Successful radiotherapy, hormone therapy (androgen deprivation), or chemotherapy should produce a declining PSA. The lowest point reached is called the "nadir" and has prognostic significance.
• Hypogonadism: Very low testosterone levels reduce prostate activity and may lower PSA. Testosterone replacement therapy can increase PSA as prostate tissue responds to restored androgen levels.

How to Improve Your PSA Levels

PSA management focuses on optimising prostate health and ensuring accurate testing rather than targeting a specific number:

Prostate Health Lifestyle Measures

• Maintain a healthy weight: Obesity is associated with more aggressive prostate cancer. A balanced diet and regular exercise support prostate health and overall wellbeing.
• Eat a Mediterranean-style diet: Rich in tomatoes (lycopene), cruciferous vegetables, oily fish, olive oil, and nuts. Epidemiological evidence suggests this dietary pattern may support prostate health.
• Stay physically active: At least 150 minutes of moderate-intensity aerobic exercise per week. Regular exercise is associated with lower risk of aggressive prostate cancer and better outcomes after diagnosis.
• Limit processed red meat: High intake of processed meats (bacon, sausages, ham) has been linked to increased prostate cancer risk in some studies.
• Moderate alcohol consumption: Heavy drinking is associated with poorer prostate health outcomes.
• Consider selenium and vitamin E with caution: The SELECT trial found no benefit from supplementation with selenium or vitamin E for prostate cancer prevention, and high-dose vitamin E may increase risk.

Ensuring Accurate PSA Testing

• Abstain from ejaculation for 48 hours before testing.
• Avoid vigorous exercise, particularly cycling, for 48 hours before testing.
• Postpone testing if you have active urinary symptoms, infection, or prostatitis. Wait until treatment is complete and symptoms have resolved.
• Disclose all medications, particularly finasteride, dutasteride, and testosterone, to your clinician.
• Test at the same laboratory: PSA assays can vary between laboratories. Serial monitoring is most reliable when the same assay is used.

Understanding Your Results in Context

• PSA velocity: The rate of PSA change over time. A rise of more than 0.75 µg/L per year is considered concerning and may prompt further investigation.
• PSA density: PSA divided by prostate volume (measured by ultrasound or MRI). A density above 0.15 is considered suspicious for cancer.
• Free-to-total PSA ratio: A lower ratio suggests higher cancer probability (see our dedicated free PSA guide).

When Should You Get Tested?

Consider a total PSA blood test if:

• You are a man aged 50 or over and want to know your prostate cancer risk.
• You are aged 45 or over with a family history of prostate cancer (father or brother) or of Black African or Caribbean descent (both groups face approximately double the average risk).
• You have lower urinary tract symptoms: difficulty starting urination, weak stream, frequency, urgency, or nocturia.
• You notice blood in your urine or semen.
• You have unexplained back, hip, or pelvic pain that might indicate advanced prostate disease.
• You are monitoring a previously diagnosed prostate condition (BPH, prostatitis, or prostate cancer).
• You are on active surveillance for low-risk prostate cancer.
• You want a comprehensive men's health assessment as part of routine screening.

Before having a PSA test, it is important to understand what the result may mean and the potential consequences of further investigation. The NHS Prostate Cancer Risk Management Programme provides information to help men make an informed decision. NICE guideline NG12 outlines the referral pathway for suspected prostate cancer.

Which Lola Health Tests Include Total PSA?

Total PSA is an essential component of men's health assessment. Lola Health includes total PSA in the following panels:

• Peak Insights - our most detailed health screen for men, including total PSA, free PSA, hormones, full lipid profile, and over 50 biomarkers.
• Vital Check — a thorough wellness panel covering prostate health alongside cardiovascular, metabolic, and hormonal markers.
• Core Health — an essential men's health check including PSA and other key biomarkers.

All Lola Health tests use venous blood draws for clinical-grade accuracy. Your results are reviewed by qualified healthcare professionals who provide personalised recommendations and, where appropriate, guidance on next steps and GP referral.